Possible benefits of low molecular weight heparinsBMJ 1994; 309 doi: https://doi.org/10.1136/bmj.309.6960.1019 (Published 15 October 1994) Cite this as: BMJ 1994;309:1019
- L Breimer
- Department of Chemical Pathology and Human Metabolism, Royal Free Hospital School of Medicine, London NW3 2QG
EDITOR, - Consideration of the main end points used in the studies included in A Leizorovicz and colleagues' meta-analysis of the possible merits of low molecular weight heparin1 illustrates certain difficulties in persuading the uninitiated of the validity of this form of pooled analysis of different groups' data. The three studies that used clinical end points (the authors' references 30, 32, and 34) account for more than …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial